Elucid

At a glance

Pricing

Enterprise.

HIPAA

Not disclosed

SOC 2

Not disclosed

EHRs

—

Founded

—

Bottom line

CCTA plaque analysis (FDA cleared 2024).

Free tier available.

Overview

Pricing

What it costs

Free tier only; no paid plans publicly disclosed.

Source: vendor pricing page. Verified May 23, 2026.

Compliance + integration

What deploys cleanly

Carries FDA 510(k) per vendor documentation. Independent attestation review is the buyer's responsibility before clinical deployment.

Peer-reviewed coverage

What the literature says

5 peer-reviewed studies indexed on PubMed evaluate Elucid in clinical contexts. The most relevant are shown below, ranked by editorial relevance score combining title match, study design, recency, and journal tier.

Late-onset unexplained epilepsy as a risk factor for cognitive impairment and dementia: Protocol for a multi-center prospective longitudinal observational study (ELUCID).

Lam AD, Johnson EL, Sarkis RA, et al.· medRxiv· 2025

Late-onset unexplained epilepsy (LoUE), defined as epilepsy onset after age 55 without an obvious cause, is an important risk factor for dementia. Studies have shown that 10-25% of individuals with LoUE develop dementia within three to four years following their first seizure. However, the mechanisms underlying progression from LoUE to dementia remain poorly understood. The goals of the ELUCID study are to identify risk factors associated with development of cognitive decline and dementia in LoUE, and to develop tools to identify patients at high risk for these outcomes and thereby establish…

Late-onset unexplained epilepsy as a risk factor for cognitive impairment and dementia: Protocol for a multi-center prospective longitudinal observational study (ELUCID).

Lam AD, Johnson EL, Sarkis RA, et al.· Epilepsia Open· 2026Observational

Late-onset unexplained epilepsy (LoUE), defined as epilepsy onset after age 55 without an obvious cause, is an important risk factor for dementia. Studies have shown that 10%-25% of individuals with LoUE develop dementia within 3-4 years following their first seizure. However, the mechanisms underlying progression from LoUE to dementia remain poorly understood. The goals of the ELUCID study are to identify risk factors associated with the development of cognitive decline and dementia in LoUE and to develop tools to identify patients at a high risk for these outcomes and thereby establi…

Intra- and inter-reader reproducibility in quantitative coronary plaque analysis on coronary computed tomography angiography.

Quintana RA, von Knebel Doeberitz P, Vatsa N, et al.· Curr Probl Cardiol· 2024

Coronary artery plaque burden, low attenuation non-calcified plaque (LAP), and pericoronary adipose tissue (PCAT) on coronary CT angiography (CCTA), have been linked to future cardiac events. The purpose of this study was to evaluate intra- and inter reader reproducibility in the quantification of coronary plaque burden and its characteristics using an artificial intelligence-enhanced semi-automated software. A total of 10 women and 6 men, aged 52 (IQR 49-58) underwent CCTA using a Siemens Somatom Force, Somatom Definition AS and Somatom Definition Flash scanners. Two expert readers utilized…

Absolute Quantification of Nucleotide Variants in Cell-Free DNA via Quantitative NGS: Clinical Application in Non-Small Cell Lung Cancer Patients.

Herbreteau G, Marcq M, Sauzay C, et al.· Cancers (Basel)· 2025

: Circulating tumor DNA (ctDNA) analysis is a powerful tool for non-invasive monitoring of tumor burden and treatment response. Reliable quantification methods are critical for the effective use of ctDNA as a tumor biomarker. Digital PCR (dPCR) offers high sensitivity and quantification, but requires the prior knowledge of tumor-specific genomic alterations. Next-generation sequencing (NGS) provides a more comprehensive approach but is semi-quantitative, relying on variant allelic fraction (VAF), which can be influenced by non-tumor cell-free DNA.: We developed a novel quantitative NGS (qNGS)…

Quantitative imaging biomarkers of coronary plaque morphology: insights from EVAPORATE.

Buckler AJ, Doros G, Kinninger A, et al.· Front Cardiovasc Med· 2023

Residual cardiovascular risk persists despite statin therapy. In REDUCE-IT, icosapent ethyl (IPE) reduced total events, but the mechanisms of benefit are not fully understood. EVAPORATE evaluated the effects of IPE on plaque characteristics by coronary computed tomography angiography (CCTA). Given the conclusion that the IPE-treated patients demonstrate that plaque burden decreases has already been published in the primary study analysis, we aimed to demonstrate whether the use of an analytic technique defined and validated in histological terms could extend the primary study in terms of whet…

See all on PubMed